186 related articles for article (PubMed ID: 31260137)
1. Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles.
Botton MR; Lu X; Zhao G; Repnikova E; Seki Y; Gaedigk A; Schadt EE; Edelmann L; Scott SA
Hum Mutat; 2019 Nov; 40(11):e37-e51. PubMed ID: 31260137
[TBL] [Abstract][Full Text] [Related]
2. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.
Suarez-Kurtz G; Genro JP; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Ribeiro-dos-Santos A; Romano-Silva MA; Santana I; Struchiner CJ
Pharmacogenomics J; 2012 Jun; 12(3):267-76. PubMed ID: 21173785
[TBL] [Abstract][Full Text] [Related]
3. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.
Pedersen RS; Brasch-Andersen C; Sim SC; Bergmann TK; Halling J; Petersen MS; Weihe P; Edvardsen H; Kristensen VN; Brøsen K; Ingelman-Sundberg M
Eur J Clin Pharmacol; 2010 Dec; 66(12):1199-205. PubMed ID: 20665013
[TBL] [Abstract][Full Text] [Related]
4. Retained duplications and deletions of CYP2C genes among primates.
Chaney ME; Piontkivska H; Tosi AJ
Mol Phylogenet Evol; 2018 Aug; 125():204-212. PubMed ID: 29631055
[TBL] [Abstract][Full Text] [Related]
5. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.
Pimenoff VN; Laval G; Comas D; Palo JU; Gut I; Cann H; Excoffier L; Sajantila A
Pharmacogenet Genomics; 2012 Dec; 22(12):846-57. PubMed ID: 23089684
[TBL] [Abstract][Full Text] [Related]
6. Differential expression and function of CYP2C isoforms in human intestine and liver.
Läpple F; von Richter O; Fromm MF; Richter T; Thon KP; Wisser H; Griese EU; Eichelbaum M; Kivistö KT
Pharmacogenetics; 2003 Sep; 13(9):565-75. PubMed ID: 12972955
[TBL] [Abstract][Full Text] [Related]
7. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
Chang TK; Yu L; Goldstein JA; Waxman DJ
Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.
Flachsbart F; Ufer M; Kleindorp R; Nikolaus S; Schreiber S; Nebel A
J Gerontol A Biol Sci Med Sci; 2011 Nov; 66(11):1186-91. PubMed ID: 21798861
[TBL] [Abstract][Full Text] [Related]
9. [Genetic polymorphism of the CYP2C subfamily].
Chiba K
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
[TBL] [Abstract][Full Text] [Related]
10. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.
Martis S; Peter I; Hulot JS; Kornreich R; Desnick RJ; Scott SA
Pharmacogenomics J; 2013 Aug; 13(4):369-77. PubMed ID: 22491019
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.
Wang X; Yu T; Liao X; Yang C; Han C; Zhu G; Huang K; Yu L; Qin W; Su H; Liu X; Peng T
Cancer Med; 2018 Apr; 7(4):966-980. PubMed ID: 29479826
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.
Saldaña-Cruz AM; León-Moreno LC; Sánchez-Corona J; Santiago DA; Mendoza-Carrera F; Castro-Martínez XH; García-Zapién AG; Morán-Moguel MC; Flores-Martínez SE
Genet Test Mol Biomarkers; 2016 Nov; 20(11):702-709. PubMed ID: 27617498
[TBL] [Abstract][Full Text] [Related]
13. A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.
Bråten LS; Haslemo T; Jukic MM; Ivanov M; Ingelman-Sundberg M; Molden E; Kringen MK
Clin Pharmacol Ther; 2021 Sep; 110(3):786-793. PubMed ID: 33759177
[TBL] [Abstract][Full Text] [Related]
14. Genetic analysis of the cytochrome P-45OIIC18 (CYP2C18) gene and a novel member of the CYP2C subfamily.
Tsuneoka Y; Matsuo Y; Okuyama E; Watanabe Y; Ichikawa Y
FEBS Lett; 1996 Apr; 384(3):281-4. PubMed ID: 8617372
[TBL] [Abstract][Full Text] [Related]
15. Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biol Pharm Bull; 2016; 39(11):1748-1759. PubMed ID: 27803446
[TBL] [Abstract][Full Text] [Related]
16. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.
Gray IC; Nobile C; Muresu R; Ford S; Spurr NK
Genomics; 1995 Jul; 28(2):328-32. PubMed ID: 8530044
[TBL] [Abstract][Full Text] [Related]
17. PharmVar GeneFocus: CYP2C19.
Botton MR; Whirl-Carrillo M; Del Tredici AL; Sangkuhl K; Cavallari LH; Agúndez JAG; Duconge J; Lee MTM; Woodahl EL; Claudio-Campos K; Daly AK; Klein TE; Pratt VM; Scott SA; Gaedigk A
Clin Pharmacol Ther; 2021 Feb; 109(2):352-366. PubMed ID: 32602114
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity.
Zubiaur P; Soria-Chacartegui P; Boone EC; Prasad B; Dinh J; Wang WY; Zugbi S; Rodríguez-Lopez A; González-Iglesias E; Leeder JS; Abad-Santos F; Gaedigk A
Clin Pharmacol Ther; 2023 Nov; 114(5):1033-1042. PubMed ID: 37528442
[TBL] [Abstract][Full Text] [Related]
19. Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population.
Bråten LS; Ingelman-Sundberg M; Jukic MM; Molden E; Kringen MK
Clin Transl Sci; 2022 Sep; 15(9):2135-2145. PubMed ID: 35668575
[TBL] [Abstract][Full Text] [Related]
20. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
Lewis DF; Dickins M; Weaver RJ; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1998 Mar; 28(3):235-68. PubMed ID: 9574814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
